Biobank

The Biobank samples are linked with rich clinical data (medical history, lifestyle factors, and genetic information), updated every 4 years. This dataset is a valuable resource for new studies to test biomarkers or validate new drug targets for treatment, saving time in the process. The Biobank is a powerful pillar for international research, with more than 50 publications in renowned scientific journals.

• Pre-Existing Data & Samples
  You don’t need to start from scratch with sample collection or patient recruitment. We have existing samples of DNA, plasma and red blood cells that are well-characterized and linked to clinical data so you can begin analyzing right away and speed up the start of your study.
• Genetic & Phenotypic Information
  With samples linked to genetic and clinical data, patients can be stratified to the right treatment based on their genetic or clinical characteristics even before the trial begins.
• Cross-Therapeutic Research
  The Biobank contains samples from patients with comorbid conditions (e.g., CVD, diabetes, kidney disease). If your study focuses on a condition that coexists with cardiovascular issues (diabetes, kidney disease), our Biobank samples can help you explore how these comorbidities might impact the effectiveness of the new treatment.

In a new study, the biobank samples of previous patients can be used for important things like:

• Screening potential biomarkers or genetic factors related to the disease or treatment
• Creating a baseline for how the disease affects people over time
• Testing whether new treatments or drugs could be effective based on the pre-existing data from the biobank samples

This can accelerate the process of setting up the study, reduce costs related to sample collection, and enhance the quality of data in your new study because you’re leveraging already collected and carefully curated samples from real patients.

Validate hypotheses quickly and demonstrate proof of concept. Access to pre-existing samples allows startups to focus on advancing their trials without the delay of sample collection.

• Speed to Market
  By tapping into an established patient database, biotech startups can access high-quality, pre-characterized biological samples and patient data, allowing them to accelerate trial timelines without starting from scratch.
• Cost-Effective & Fast
  The pre-existing patient cohort offers a reliable and affordable resource, reducing time-to-market and enabling startups to leverage existing data for early-stage clinical trials.
• Rapid Validation of Biomarkers and Targets
  The extensive dataset supports target discovery, biomarker validation, and patient stratification, helping startups advance their therapeutic areas with less risk and lower investment.